A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Bristol-Myers Squibb
Alterome Therapeutics, Inc.
Revolution Medicines, Inc.
Erasca, Inc.
Revolution Medicines, Inc.